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Abstract 
Motivation: Small Ubiquitin-related modifier (SUMO) proteins are widely expressed in eukaryotic 
cells, which are reversibly coupled to their substrates by motif recognition, called sumoylation. Two 
interesting questions are 1) how many potential SUMO substrates may be included in mammalian 
proteomes, such as human and mouse, 2) and given a SUMO substrate, can we recognize its 
sumoylation sites? To answer these two questions, previous prediction systems of SUMO substrates 
mainly adopted the pattern recognit ion methods, which could get high sensitivity with relatively too 
many potential false positives. So we use phylogenetic conservation between mouse and human to 
reduce the number of potential false positives. 
Results: We first use two major patterns of a potential SUMO substrate: an NLS (Nuclear 
Localization Signal) and a consensus motif y-K-X-E, where y meant a hydrophobic amino acid. So 
we followed a simple rule to predict the SUMO substrates: the sub-cellular localization of a given 
protein must be predicted as nuclear by PSORT II, and the protein must have at least one consensus 
motif y(A, F, I, L, M, V, W)-K-X-E. After the above methods, there are still too many predicted 
positives. To eliminate the potential false positives, we used the orthology information between 
mouse and human, and followed the rule that at least one consensus motif should be at the same 
position after sequence alignment of the ortholog pair. We got 2,683 potential SUMO substrates in 
both mouse and human, with 58 out of 79 known SUMO substrates in human predicted correctly. 
For the sumoylation sites prediction, our method got nearly the same sensitivity as the existed tool 
SUMOplot, with 42 against 42 (high probability) or 44 (all) true positives of 54 known sumoylation 
sites respectively. But our method outperformed SUMOplot significantly by specificity, with 74 
against 152 (high probability) or 324 (all) predicted sumoylation sites respectively. So our method 
greatly reduced the number of potential false positives while still kept a satisfying sensitivity. 
Availability: The software SSP (SUMO Substrate and Site Prediction) 1.0 for Windows system, 
written by Delphi, is available from http://973-proteinweb.ustc.edu.cn/sumo/.  
Contact: yxue@mail.ustc.edu.cn, ffzhou@ustc.edu  
 
 
 
Introduction 
Small Ubiquitin-related MOdifier (SUMO) proteins are ubiquitously expressed in eukaryotic 
cells (Melchior F. et al., 2003), and implicatedly regulate various cellular processes, e.g. stress 
responsing (Huang TT et al., 2003), cell-cycle progression (Muller S et al., 2001; Pinsky BA et al., 
2002; Seeler JS et al., 2003), and gene expression (Muller S et al., 2004), etc . 
    SUMO proteins belong to the superfamily of Ubiquitin-like modifiers (UBLs) (Schwartz DC et 
al., 2003), and consist of three components in mammalian: SUMO-1, SUMO-2 and SUMO-3 
(Saitoh H et al., 2000). Recently, another component SUMO-4 was discovered in human (Bohren 
KM et al., 2004). SUMO proteins are highly conserved from yeast to human. 
There are only 12 experiment-verified SUMO substrates before 2000 (Melchior F, 2000). But 
now, > 60 SUMO substrates were discovered (Seeler JS et al., 2003) and it becomes a fascinating 
hot area to search for new SUMO substrates in mammlians, especially in human. 
Conventional experimental approaches can identify SUMO substrates, but they are tedious and 
time-consuming. Small-scale analysis of SUMO substrates could improve the efficiency by the 
method of affinity chromatography-coupled high-pressure liquid chromatography/tandem mass 
spectrometry (Zhao Y et al., 2004); yet only 4 previously characterized and 18 novel potential 
SUMO substrates were found. 
The majority of the SUMO substrates have a consensus motif with four amino acids. There are 
several motifs proposed in the literatures: such as y-K-X-E (Seeler JS, et. al. 2003, Zhao Y, et. al. 
2004), and [VILAFP]-K-X-[EDNGP] (Puntervoll P,  et. al. 2003), etc. We are mainly focusing on 
reducing the number of potential false positives by the phylogenetic conservation in this work. So 
we just choose the former one as the consensus motif. And a nuclear localization signal (NLS) 
suffices to produce a SUMO conjugate in vivo (Manuel S et al., 2001), with only a few exceptions 
(Seeler JS et al., 2003).  
With these molecular characteristics, it’s possible to predict the SUMO substrates in silico by 
pattern recognition, which has been widely used in the biological domain/motif predictions, e.g. the 
PROSITE database (Falquet L et al., 2002), and the transcription factor binding sites (TFBSs) 
(Quandt, K et al., 1995), etc . But such methods will also generate too many false positive results. We 
found that rVista, combining the pattern recognition and phylogenetic conservation approaches, has 
much better predicting performance of transcription factor binding sites than before (Loots GG et al., 
2002). To eliminate the potential false positives satisfying the above patterns, here we combined the 
pattern recognition and phylogenetic conservation approaches to predict the SUMO substrates and 
got 2,683 results in both mouse and human. 
 
Methods 
We downloaded the orthology-relationship data of mouse and human with the corresponding 
sequences from the InParanoid database (Version 2.6, 30/03/2004) (Remm M et al., 2001), which 
contains orthology information among 7 model organisms, including E.coli, S.cerevisiae, A.thaliana, 
C.elegans, D.melanogaster, M.musculus and H.sapiens. Here we only used the orthology 
information between human and mouse. 
For the 34,499 mouse sequences and 36,379 human sequences in InParanoid, we firstly 
scanned the sequences for the consensus motif y(A, F, I, L, M, V, W)-K-X-E in mouse and human 
respectively. Sequences without such motif were excluded. Then we got 13,026 sequences in mouse 
and human respectively. 
By PSORT II (Nakai K et al., 1999), we predicted the sub-cellular localization of the retained 
sequences. Only proteins with predicted nuclear localization were retained. After this step, there 
were 6,662 sequences in mouse and 7649 in human respectively. 
In order to eliminate the potential false positive results, we followed a simple rule below: for 
the pairwise orthologs among the retained mouse and human proteins, they must have at least one 
consensus SUMO substrate motif at the same position after sequence alignment. So proteins without 
orthologs were excluded firstly. We aligned the sequences of the remaining ortholog pairs 
respectively by ClustalW (Thompson JD et al., 1994). After the sequence alignment, orthologs 
sharing no SUMO target motif at the same position were also excluded.  Finally we got 2,683 
proteins in both mouse and human. 
 
 
 
Results and Discussion 
Using homology information to eliminate the potential false positive 
Since SUMO substrates and their sites in mammalians especially in human is more important 
and urgent than in other species recently, and the orthology information between human and mouse 
is more abundant and integrated, we used the phylogenetic conservation between human and mouse 
to reduce the potential false positives.  
We got 67 experiment-verified sumoylation sites from the published work. The sequence logo 
of the motifs was generated using relative entropy (Gorodkin J et al., 1997) (see in Figure 1). 
Although there are some atypical amino acid which could rarely appear in the first or fourth position, 
we follow this simple motif, y(A, F, I, L, M, V, W)-K-X-E, which holds for the majority of known 
sumoylation sites. 
Most of the SUMO substrates are nuclear proteins, with only a few exceptions, such as the 
cytoplasmic proteins GLUT1, and GLUT4. So we use PSORT II to predict the sub-cellular locations 
of the potential proteins. The proteins without a “nuc” (nuclear) hit by PSORT II prediction were 
excluded. 
We checked the published references related to SUMO, and 79 experiment-verified SUMO 
substrates were listed in TABLE 1. Our method can predict 58 of them as true positives, with 
accuracy ~73%. For the wrongly predicted SUMO substrates, six proteins, such as CREB and Daxx, 
have no consensus motif, another nine proteins don’t get a “nuc” (nuclear) hit by PSORT II 
prediction and the other six proteins were excluded by orthology information.  
By orthology information, we reduced the predicted results 7, 649 to 2, 683 in human. 64 out of 
74 known SUMO substrates can be predicted correctly with only the consensus motif and the 
sub-celluar localization. Combining with the orthology restriction, another six true results were 
missed. So it can be concluded that phylogenetic conservation could be a great help to SUMO 
substrate prediction. 
 
Comparison to an existing tool SUMOplot for sumoylation sites prediction 
If a SUMO substrate was predicted or verified, could we recognize the sumoylation sites 
correctly? In order to answer this question, we compared our method with the existing tool 
SUMOplot (http://www.abgent.com/default.php?page=sumoplot), which is based on pattern 
recognition only. 
54 verified sumoylation sites of 37 known SUMO substrates were chosen. We only considered 
the SUMO substrates that can be predicted correctly by our method. And the results were shown in 
TABLE 2. 
Here we defined the sensitivity (Sn) and specificity (Sp) of the prediction as: Sn=m/N, and 
Sp=m/M respectively, where m is the number of predicted sumoylation sites which are true positives, 
N is the number of experiment-verified sumoylation sites, and M is the number of the predicted sites. 
For total 54 known sumoylation sites, our method could recover 42 of them with the Sn of 
~78%, which is similar to the SUMOplot results ~78% (Motifs with high probability) or ~81% (all). 
Yet the specificity of our approach is significantly improved to ~57% (42 in 74 totally), comparing 
to SUMOplot ~28% (Motifs with high probability) or ~14% (all). 
    Although we missed several true results, our method successfully reduced the number of the 
potential false positives significantly with slightly reducing the sensitivity. For identification of 
SUMO substrates and sites in other organisms, we may use several available systems, such as ELM 
(Puntervoll P 2003).  
    For convenience and data security, we design the program for Windows version written in 
Delphi, which can be used in local. 
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Figure 1 - The sequence logo of verified sumoylation motifs 
Curated from the published work, we got 67 experiment-verified sumoylation sites. And the 
sequence logo of the motifs was generated using relative entropy.  
 
TABLE 1 – The prediction results of the known SUMO substrates 
79 experiment-verified SUMO substrates are listed. Our method can predict 58 of them correctly 
(~73%). For the wrongly predicted SUMO substrates, six proteins, such as CREB and Daxx, have no 
consensus motif, another nine proteins don’t get a “nuc” (nuclear) hit by PSORT II prediction, and 
the left six proteins were excluded by orthology information.  
 
TABLE 2 – The comparison of the sumoylation site prediction against SUMOplot 
Fifty-four verified sumoylation sites of 37 known SUMO substrates were chosen. Our method got 
nearly the same sensitivity as the existed tool SUMOplot, with 42 against 42 (high probability) or 44 
(all) true positives respectively. But our method outperformed SUMOplot significantly by specificity, 
with 74 against 152 (high probability) or 324 (all) predicted sumoylation sites respectively. So our 
method greatly reduced the number of false positives while still kept a satisfying sensitivity. 
 
Figure 1
Protein name Sumoylation sites References Prediction
AP-2  alpha K10 12072434 Yes
AP-2  beta K10 12072434 Yes
AP-2  gamma K10 12072434 Yes
AR (androgen receptor) K386, K520 11121022 Yes
ARNT (aryl hydrocarbon receptor nuclear transporter) K245 12354770 Yes
Axin 12223491 Yes
Bach2 15060166 Yes
C/EBP beta-1 K173 12810706 Yes
C/EBPalpha (CCAAT/enhancer-binding protein alpha) K159 12511558 Yes
c-Jun K229 10788439 Yes
c-Myb K503, K527 12631292 Yes
CREB (cAMP-response element-binding protein) K285, K304 12552083 No a
CtBP1 K428 12769861 No b
Daxx K630, K631 12150977 No a
Dnmt3a 14752048 No b
Dnmt3b 14752048 Yes
Dynamin -1 15123615 Yes
Dynamin -2 15123615 Yes
Dynamin -3 15123615 Yes
Elk-1 K230, K249 14992729 Yes
FAK (Focal adhesion kinase) K152 14500712 Yes
GATA-2 12750312 Yes
GLUT1 10655495 No b
GLUT4 11842083 No b
GR (glucocorticoid receptor) K277, K293 12144530 Yes
GRIP1 K239, K731, and K788 12060666 Yes
HDAC1 K444, K476 11960997 No b
HDAC4 K559 12032081 No c
HIPK2 K1182 10535925 Yes
histone H4 14578449 No a
hnRNP C K237 15082759 Yes
hnRNP M 15082759 No b
HSF1 (Heat shock transcription factor 1) K298 11514557 Yes
HSF2 (Heat shock transcription factor 2) K82 11278381 Yes
IkappaBalpha K21 9734360 Yes
IRF-1 (Interferon regulatory factor-1) 12387893 No a
LEF1 K27, K269 11731474 Yes
Mdm2 11384992 Yes
MR (mineralocorticoid receptor) 14500761 Yes
NEMO/IKKgamma K277, K309 14651848 Yes
NFAT1 15117942 Yes
Nurr1 (NR4A2, RNR-1,TINUR, HZF-3) K91, K577 14559918 Yes
p300/CBP K1017, K1029 12718889 Yes
p53 K386 10788439 No c
p73alpha K627 10961991 Yes
PC2 12679040 Yes
Pdx1 (Pancreatic duodenal homeobox-1) 12488243 Yes
PIAS1 12077349 No c
PIASx-beta 12077349 No a
PLZF (Promyelocytic leukemia zinc finger) K242 14527952 No c
PML (promyelocytic leukaemia protein) K65, K160, and K490 10525530 Yes
PPAR-gamma 15123625 No c
PR (progesterone receptor) K388 12529333 Yes
RanBP2/NUP358 15037602 Yes
RanGAP1 K526 9442102 No b
SALL1 K1086 12200128 Yes
SATB2 14701874 Yes
SENP1 14563852 Yes
Smad4 K113, K159 12621041 Yes
Sox6 A Yes
Sox9 A Yes
Sp100 K297 10212234 No c
Sp3 K539 12419227 Yes
SREBP-1a K123, K418 12615929 Yes
SREBP-2 K464 12615929 No b
SRF (serum response factor) K147 12788062 Yes
STAT1 K703 12764129 No b
steroid receptor coactivator SRC-1/NCoA-1 K732, K774 12529333 Yes
Tcf-4 K297 12727872 Yes
TDG K330 11889051 Yes
TEL K99 12626745 Yes
TFII-I 15016812 Yes
TIF1alpha K690, K708 11313457 Yes
TOPO I K117, K153 12439742 Yes
topoisomerase II alpha 14597774 Yes
topoisomerase II beta 12832072 Yes
Topors K560 14516784 Yes
WRN 10806190 Yes
zinc finger protein APA-1 12370286 No a
a No consensus motif (6 proteins)
A R. Fernandez-Lloris, F. Ventura1 and R. T. Hay. (2002) Post-translational Sox6 protein
modification by SUMO-1. 28th Meeting of the Federation of European Biochemical Societies
20-25, Istanbul, Turkey
b Not "nuc" (nuclear) hit by PSORT II prediction (9 proteins)
c Excluded by orthlogy information (6 proteins)
TABLE 1
Verified SSP 1.0 SUMOplot
AP-2 alpha K10 IKYEa 1/1b; (1/4)c
AP-2 beta K10 IKYE 1/1; (1/5)
AP-2 gamma K10 IKYE 1/1; (1/4)
AR (androgen receptor) K386, K520 IKLE, VKSE 2/3; (2/6)
ARNT (aryl hydrocarbon receptor nuclear
transporter)
K245 VKKE 0/2; (0/5)
C/EBP beta-1 K173 LKAE 1/2; (1/4)
C/EBPalpha (CCAAT/enhancer-binding
protein alpha)
K159 LKAE 1/1; (1/1)
c-Jun K229 AKME, LKEE, IKAE 1/3; (1/4)
c-Myb K503, K527 IKQE, IKQE 2/5; (2/10)
Elk-1 K230, K249 VKVE 2/2; (2/4)
FAK (Focal adhesion kinase) K152 WKYE 1/5; (1/17)
GR (glucocorticoid receptor) K277, K293 VKTE, IKQE, VKRE 0/1; (0/5)
GRIP1 K239, K731, K788 VKLE, MKQE 2/7; (2/17)
HIPK2 K1182 LKIE, LKPE 0/3; (0/7)
hnRNP C K237 IKKE, VKME 0/4; (1/12)
HSF1 (Heat shock transcription factor 1) K298
VKPE, LKSE, MKHE,
VKEE
1/6; (1/9)
HSF2 (Heat shock transcription factor 2) K82 VKQE, IKQE, LKSE 1/6; (1/9)
IkappaBalpha K21 LKKE, MKDE 1/4; (1/4)
LEF1 K27, K269 FKDE, VKQE 2/3; (2/7)
NEMO/IKKgamma K277, K309 AKQE, LKEE 1/8; (1/13)
Nurr1 (NR4A2, RNR-1,TINUR, HZF-3) K91, K577 IKVE, LKLE 2/4; (2/10)
p300/CBP K1017, K1029
MKTE, VKEE, VKVE,
VKEE, FKPE
2/11; (2/22)
p73alpha K627 IKEE 1/3; (1/7)
PML (promyelocytic leukaemia protein) K65, K160, K490 LKHE, IKME 3/6; (3/7)
PR (progesterone receptor) K388 IKEE 1/3; (1/6)
SALL1 K1086 IKTE, IKTE 1/7; (1/15)
Smad4 K113, K159 VKDE 1/3; (1/7)
Sp3 K539 IKDE, IKEE 1/3; (1/5)
SREBP-1a K123, K418 IKEE, LKQE, VKTE 2/7; (2/11)
SRF (serum response factor) K147 IKME 1/1; (1/3)
steroid receptor coactivator SRC-1/ NCoA-1 K732, K774
AKAE, IKLE, VKVE,
IKLE, IKSE
1/7; (1/13)
Tcf-4 K297 FKDE, VKQE 1/6; (1/10)
TDG K330 VKEE 0/0; (0/8)
TEL K99 IKQE 0/2; (0/3)
TIF1alpha K690, K708 IKQE, VKQE, IKLE 2/5; (2/11)
TOPO I K117, K153
IKKE, IKTE, IKEE,
FKIE, IKGE, MKLE
2/12; (2/29)
Topors K560 LKRE 0/4; (1/10)
Protein name
Sumoylation sites
Total sites 54 42/74
d 42/152; (44/324)
a SSP 1.0 hits are in bold character font
b SUMOplot hits (Motifs with high probability) / total predicted sites (Motifs with high probability)
c SUMOplot hits (all) / total predicted sites (all)
d SSP 1.0 hits/total predicted sites
TABLE 2
